From AAV to Biomarkers—Your 2025 Roadmap

Support for Your Early-Phase Gene Therapy Program

At Altasciences, we are committed to advancing gene therapies with precision and efficiency. In addition to hundreds of pre-screened AAV nonhuman primates (NHPs) available for gene therapy programs and decades of bioanalytical, nonclinical, and clinical expertise―we’ve compiled a comprehensive list of resources below:

A Comprehensive Guide to Gene Therapy and Improving AAV Efficiency

Learn more about our track record, expertise in navigating regulatory requirements, and how we ensure the safety and efficacy of AAV-based therapies (three case studies included).

In-House AAV Pre-Screening

Detailed information on our in-house AAV pre-screening methods for removing nonhuman primates from toxicology studies if they have antibodies against AAV8 serotypes. It covers two main assays: total antibody screening (TAb) and neutralizing antibody screening (NAb).

Expert Insights on Cell and Gene Therapy Development

This scientific journal reviews considerations for nonclinical cell and gene therapy development, including expert approaches to mitigate complex challenges, improve study efficiency, and maximize translational opportunities to first-in-human trials.

Altasciences’ Biomarkers by Indication

Our expertise in biomarker analysis supports critical go/no-go decision making by providing insight into a drug’s efficacy, safety, and mechanism of action. Assessed early in the drug development process, biomarker assays can validate targets and identify potential toxicity.

Ready to get your gene therapy development program started? Speak with one of our experts.